Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 18;5(5):CD004596.
doi: 10.1002/14651858.CD004596.pub3.

Drug therapy for symptoms associated with anxiety in adult palliative care patients

Susan Salt  1 , Caroline A Mulvaney  2 , Nancy J Preston  3
Affiliations

Drug therapy for symptoms associated with anxiety in adult palliative care patients

Susan Salt et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an update of a Cochrane Review first published in 2004 (Issue 1) and previously updated in 2012 (Issue 10). Anxiety is common in palliative care patients. It can be a natural response to the complex uncertainty of having a life-limiting illness or impending death, but it may represent a clinically significant issue in its own right.

Objectives: To assess the effectiveness of drug therapy for treating symptoms of anxiety in adults with a progressive life-limiting illness who are thought to be in their last year of life.

Search methods: We ran the searches for this update to May 2016. We searched the CENTRAL, MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), PsychLIT (Silver Platter) and PsycINFO (Ovid). We searched seven trials registers and seven pharmaceutical industry trials registers. We handsearched the conference abstracts of the European Association of Palliative Care.

Selection criteria: Randomised controlled trials which examined the effect of drug therapy for the treatment of symptoms of anxiety in adult palliative care patients, that is, people with a known progressive life-limiting illness that is no longer responsive to curative treatment, including advanced heart, respiratory and neurological diseases (including dementia). Comparator treatments included placebo; another drug therapy or different dose schedule; or a non-drug intervention such as counselling, cognitive behaviour therapies or relaxation therapies.

Data collection and analysis: Two review authors independently screened titles and abstracts to identify potentially relevant papers for inclusion in the review. We sought full-text reports for all papers retained at this stage and two reviews authors independently assessed these for inclusion in the review. We planned to assess risk of bias and extract data including information on adverse events. We planned to assess the evidence using GRADE and to create a 'Summary of findings' table.

Main results: In this update, we identified 707 potentially relevant papers and of these we sought the full-text reports of 10 papers. On examination of these full-text reports, we excluded eight and two are awaiting classification as we have insufficient information to make a decision. Thus, in this update, we found no studies which met our inclusion criteria. For the original review, we identified, and then excluded, the full-text reports of six potentially relevant studies. For the 2012 update, we sought, and excluded, two full-text reports. Thus, we found no studies that assessed the effectiveness of drugs to treat symptoms of anxiety in palliative care patients.

Authors' conclusions: There is a lack of evidence to draw a conclusion about the effectiveness of drug therapy for symptoms of anxiety in adult palliative care patients. To date, we have found no studies that meet the inclusion criteria for this review. We are awaiting further information for two studies which may be included in a future update. Randomised controlled trials which assess management of anxiety as a primary endpoint are required to establish the benefits and harms of drug therapy for the treatment of anxiety in palliative care.

PubMed Disclaimer

Conflict of interest statement

SS: none known; SS is a specialist in palliative care and manages patients with anxiety.

CM: none known.

NP: none known.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Barreto 1996 {published data only}
    1. Barreto P, Bayes R, Comas MD, Martinez E, Pascual A, Roca J, et al. Assessment of the perception and worries [corrected] in terminally ill patients in Spain. Journal of Palliative Care 1996;12:43‐6. [PUBMED: 8708851] - PubMed
Bruera 1986 {published data only}
    1. Bruera E, Carraro S, Roca E, Barugel M, Chacon R. Double‐blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients. Cancer Treatment Reports 1986;70:295‐8. [PUBMED: 3512080] - PubMed
Butters 1992 {published data only}
    1. Butters E, Higginson I, George R, Smits A, McCarthy M. Assessing the symptoms, anxiety and practical needs of HIV/AIDS patients receiving palliative care. Quality of Life Research 1992;1:47‐51. [PUBMED: 1284465] - PubMed
Centeno 2012 {published data only}
    1. Centeno C, Sanz A, Cuervo MA, Ramos D, Hernansanz S, Gonzalez J, et al. Multicentre, double‐blind, randomised placebo‐controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients. British Medical Journal Supportive and Palliative Care 2012;2(4):328‐33. [DOI: 10.1136/bmjspcare-2011-000093] - DOI - PubMed
Daubert 2014 {published data only}
    1. Daubert E, Bolesta S. Effect of lorazepam versus morphine on quality of life in hospice patients with dyspnea and anxiety. Journal of the American Pharmacists Association 2014;54(2):e193.
Dauchy 2015 {published data only}
    1. Dauchy S, Majed L, Saltel P, Reich M, Rouby P, Lopez C, et al. A randomized, double‐blind, placebo‐controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer. Psycho‐Oncology 2015;24:332. [DOI: 10.1002/pon.3874] - DOI
Fernandez 1987 {published data only}
    1. Fernandez F, Adams F, Holmes VF. Analgesic effect of alprazolam in patients with chronic, organic pain of malignant origin. Journal of Clinical Psychopharmacology 1987;7:167‐9. [PUBMED: 3597802] - PubMed
Grob 2011 {published data only}
    1. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced‐stage cancer. Archives of General Psychiatry 2011;68(1):71‐8. [DOI: 10.1001/archgenpsychiatry.2010.116] - DOI - PubMed
Holland 1991 {published data only}
    1. Holland JC, Morrow GR, Schmale A, Dragatis, L, Stefanek M, Berenson S, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. Journal of Clinical Oncology 1991;9:1004‐11. [PUBMED: 2033413] - PubMed
Irwin 2013 {published data only}
    1. Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28‐day open‐label proof‐of‐concept trial. Journal of Palliative Medicine 2013;16(8):958‐65. [DOI: 10.1089/jpm.2012.0617] - DOI - PMC - PubMed
Koralewski 2002 {published data only}
    1. Koralewski P, Nawara I, Cegielski W, Betkowska‐Oleksik K, Kosobucki R. The assessment of usefulness of alprazolam and buspiron in anxiolytic therapy of cancer patients. Onkologia Polska 2002;5(1):11‐8.
Kronish 2012 {published data only}
    1. Kronish IM, Chaplin WF, Rieckmann N, Burg MM, Davidson KW. The effect of enhanced depression care on anxiety symptoms in acute coronary syndrome patients: findings from the COPES trial. Psychotherapy and Psychosomatics 2012;81(4):245‐7. [DOI: 10.1159/000332439] - DOI - PMC - PubMed
Ng 2014 {published data only}
    1. Ng CG, Boks MP, Roes KC, Zainal NZ, Sulaiman AH, Tan SB, et al. Rapid response to methylphenidate as an add‐on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four‐week, randomized, double‐blinded, placebo‐controlled study. European Neuropsychopharmacology 2014;24(4):491‐8. [DOI: 10.1016/j.euroneuro.2014.01.016] - DOI - PubMed
Wald 1993 {published data only}
    1. Walt TG, Kathol RG, Noyes R Jr, Carroll BT, Clamon GH. Rapid relief of anxiety in cancer patients with both alprazolam and placebo. Psychosomatics 1993;34:324‐32. [PUBMED: 8351307] - PubMed
Yazici 2012 {published data only}
    1. Yazici AE, Erdem P, Erdem A, Yazici K, Acar ST, Basterzi AD, et al. Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: an open placebo‐controlled study. Klinik Psikofarmakoloji Bulteni 2012;22(1):23‐30. [DOI: 10.5455/bcp.20120215011558] - DOI
Ziolko 2004 {published data only}
    1. Ziolko E, Knopik J, Bucior J, Foltyn W, Jastrzebska‐Okon K, Tomczyk A, et al. Evaluation of usefulness and effectiveness of anxiolytic therapies in neoplastic diseases. Polski Merkuriusz Lekarski 2004;XVI:561‐4. [PUBMED: 15510897] - PubMed

References to studies awaiting assessment

Hart 2012 {published data only}
    1. Hart DE, Corna NE, Horwood F, Maingay G. Randomised control trial of intranasal midazolam or oral lorazepam for the relief of dyspnoea in severe respiratory disease. American Journal of Respiratory and Critical Care Medicine 2012;185:A2953.
Usmani 2013 {published data only}
    1. Usmani ZA. Paroxetine for anxiety in patients with chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000458730 Date first registered: 22 April 2013.

Additional references

Baldwin 2005
    1. Baldwin DS, Nutt DJ, Bandelow B, Bond A, Davidson JRT, Boer JA, et al. Evidence‐based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19:567‐96. [DOI: 10.1177/0269881105059253] - DOI - PubMed
Bastien 2001
    1. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine 2001;2:297‐307. [PUBMED: 11438246] - PubMed
Beck 1961
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561‐71. [PUBMED: 13688369] - PubMed
Beck 1988
    1. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988;56:893‐7. [PUBMED: 3204199] - PubMed
Bradburn 1969
    1. Bradburn N. The Structure of Psychological Well‐being. Chicago (IL): Aldine, 1969.
Breitbart 1996
    1. Breitbart W, Jacobsen PB. Psychiatric symptom management in terminal care. Clinics in Geriatric Medicine 1996;12(2):329‐47. [PUBMED: 8799351] - PubMed
Bruera 1991
    1. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. Journal of Palliative Care 1991;7(2):6‐9. [PUBMED: 1714502] - PubMed
Buysse 1989
    1. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research 1989;28:192‐213. [PUBMED: 2748771] - PubMed
de Haes 1996
    1. Haes JCJM, Olschewski M, Fayers P, Visser MRM, Cull A, Hopwood P, et al. The Rotterdam Symptom Checklist (RSCL). A Manual. Northern Centre for Healthcare Research (NCH), University of Groningen, the Netherlands 1996.
Derogatis 1983
    1. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychological Medicine 1983;33:67‐75. [PUBMED: 6622612] - PubMed
DSM‐5 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5). Arlington (VA): American Psychiatric Association, 2013.
DSM‐III 1980
    1. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Arlington (VA): American Psychological Association, 1980.
DSM‐IV 1994
    1. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Arlington (VA): American Psychological Association, 1994.
DSM‐IV‐TR 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington (VA): American Psychiatric Association, 2000.
DSM‐R 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington (VA): American Psychiatric Association, 1987.
Hamilton 1959
    1. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50‐5. [DOI: 10.1111/j.2044-8341.1959.tb00467.x] - DOI - PubMed
Hearn 1999
    1. Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Quality in Health Care : QHC 1999;8:219‐27. - PMC - PubMed
Henderson 2006
    1. Henderson M, MacGregor E, Sykes N, Hotopf M. The use of benzodiazepines in palliative care. Palliative Medicine 2006;20(4):407‐12. [PUBMED: 16875110] - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higginson 1993
    1. Higginson I. Audit methods: a community schedule. In: Higginson I editor(s). Clinical Audit in Palliative Care. Oxford: Radcliffe Medical Press, 1993:34‐47.
ICD‐10 2010
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Geneva: World Health Organization 2010.
Jackson 2000
    1. Jackson KC, Lipman AG. Anxiety in palliative care patients. Journal of Pharmaceutical Care in Pain and Symptom Control 2000;7(4):23‐35.
Jones 1991
    1. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory Medicine 1991;85 (Suppl B):25‐31. [PUBMED: 1759018] - PubMed
Khojainova 2002
    1. Khojainova N, Santiago‐Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. Journal of Pain and Symptom Management 2002;23(4):346‐50. [PUBMED: 11997204] - PubMed
Klein 2011
    1. Klein C, Lang U, Bükki J, Sittl R, Ostgathe C. Pain management and symptom‐oriented drug therapy in palliative care. Breast Care 2011;6:27‐34. [DOI: 10.1159/000324702] - DOI - PMC - PubMed
Kolva 2011
    1. Kolva E, Rosenfeld B, Pessin H, Breitbart W, Brescia R. Anxiety in terminally ill cancer patients. Journal of Pain and Symptom Management 2011; Vol. 42, issue 5:691‐701. [DOI: 10.1016/j.jpainsymman.2011.01.013] - DOI - PMC - PubMed
Maguire 1993
    1. Maguire P, Faulkner A, Regnard C. Managing the anxious patient with advancing disease ‐ a flow diagram. Palliative Medicine 1993;7:239‐44. [PUBMED: 8261191] - PubMed
Mintzer 2001
    1. Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. International Journal of Geriatric Psychiatry 2001;16(Suppl 1):S71‐7. [PUBMED: 11748790] - PubMed
Mitchell 2011
    1. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative‐care settings: a meta‐analysis of 94 interview‐based studies. Lancet Oncology 2011;12(2):160‐74. [DOI: 10.1016/S1470-2045(11)70002-X] - DOI - PubMed
Moorey 2009
    1. Moorey S, Cort E, Kapari M, Monroe B, Hansford P, Mannix K, et al. A cluster randomized controlled trial of cognitive behaviour therapy for common mental disorders in patients with advanced cancer. Psychological Medicine 2009;39(5):713‐23. [DOI: 10.1017/S0033291708004169] - DOI - PubMed
National Consensus Project 2009
    1. National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, Second edition 2009.
National Palliative and End of Care 2015
    1. National Palliative and End of Care Partnership. Ambitions for palliative and end of life care: a national framework for local action 2015‐2020, 2015. endoflifecareambitions.org.uk/wp‐content/uploads/2015/09/Ambitions‐for‐P... (accessed 11 March 2017).
NICE 2015
    1. National Institute for Health and Care Excellence. Care of dying adults in the last days of life. NICE guideline NG31, 2015. www.nice.org.uk/guidance/ng31 (accessed 14 December 2016). - PubMed
NICE 2004
    1. National Institute for Clinical Excellence. Improving supportive and palliative care for adults with cancer. The manual. Cancer Service Guideline (CSG4), 2004. www.nice.org.uk/guidance/csg4 (accessed 14 December 2016).
NICE 2011a
    1. National Institute for Health and Care Excellence. End of life care for adults. Quality standard (QS13), 2011. www.nice.org.uk/guidance/qs13 (accessed 11 March 2017).
NICE 2011b
    1. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults. Clinical guideline (CG113), 2011. https://www.nice.org.uk/guidance/cg113/chapter/1‐guidance (accessed 14/12/16) (accessed 14 December 2016).
Noyes 1998
    1. Noyes R, Holt CS, Massie MJ. Anxiety disorders. In: Holland JC, Breitbart W editor(s). Psycho‐oncology. New York (NY): Oxford University Press, 1998:548‐63.
Nübling 2012
    1. Nübling G, Allmendinger S, Lorenzl S. Drug therapy of anxiety and fear in palliative care patients with cancer or other illnesses: a systematic review. Schmerz (Berlin, Germany) 2012;26(5):537‐49. [DOI: 10.1007/s00482-012-1241-6] - DOI - PubMed
Payne 1995
    1. Payne D. Cognitive Factors in Breakthrough Pain [PhD dissertation]. Louisville (KY): University of Louisville, 1995.
Pollock 1979
    1. Pollock V, Cho DW, Reker D, Volavka J. Profile of Mood States: the factors and their physiological correlates. Journal of Nervous and Mental Disease 1979;167(10):612‐4. [PUBMED: 226658] - PubMed
Robins 1981
    1. Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Archives of General Psychiatry 1981;38(4):381‐9. [PUBMED: 6260053] - PubMed
Roth 2007
    1. Roth AJ, Massie MJ. Anxiety and its management in advanced cancer. Current Opinion in Supportive and Palliative Care 2007;1(1):50‐6. [DOI: 10.1097/SPC.0b013e32813aeb23] - DOI - PubMed
Schulz 2010
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:697‐702. [DOI: 10.1136/bmj.c332] - DOI - PMC - PubMed
Soldatos 2000
    1. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD‐10 criteria. Journal of Psychosomatic Research 2000;48:555‐60. [PUBMED: 11033374] - PubMed
Spencer 2010
    1. Spencer R, Nilsson M, Wright A, Pirl W, Prigerson H. Anxiety disorders in advanced cancer patients: correlates and predictors of end‐of‐life outcomes. Cancer 2010;116(7):1810‐9. [DOI: 10.1002/cncr.24954] - DOI - PMC - PubMed
Spielberger 1983
    1. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State‐Trait Anxiety Inventory. Palo Alto (CA): Consulting Psychologists Press, 1983.
Thielking 2003
    1. Thielking PD. Cancer pain and anxiety. Current Pain and Headache Reports 2003;7:249‐61. - PubMed
Traeger 2012
    1. Traeger L, Greer JA, Fernandez‐Robles C, Temel JS, Pirl WF. Evidence‐based treatment of anxiety in patients with cancer. Journal of Clinical Oncology 2012;30:1197‐205. [DOI: 10.1200/JCO.2011.39.5632] - DOI - PubMed
Wilson 2007
    1. Wilson KG, Chochinov HM, Skirko MG, Allard P, Chary S, Gagnon PR, et al. Depression and anxiety disorders in palliative cancer care. Journal of Pain and Symptom Management 2007;33(2):118‐29. [DOI: 10.1016/j.jpainsymman.2006.07.016] - DOI - PubMed
Zigmond 1983
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 1983;67(6):361‐70. [PUBMED: 6880820] - PubMed

References to other published versions of this review

Candy 2012
    1. Candy B, Jackson KC, Jones L, Tookman A, King M. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD004596.pub2] - DOI - PubMed
Jackson 2004
    1. Jackson KC, Lipman AG. Drug therapy for anxiety in adult palliative care patients. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004596] - DOI - PubMed

Publication types

Substances